NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant a ...

Core Viewpoint - The complaint against Alto alleges violations of federal securities laws due to misleading statements regarding the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) and the overstated prospects of the company's business and financial performance [2]. Group 1: Company Performance and Stock Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 on October 23, 2024 [3]. - Following the announcement, Jeffries reduced its price target for Alto from $33 to $17, indicating concerns about the company's biomarker approach to central nervous system disorders and psychiatry [4]. Group 2: Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [5]. - The law firm Faruqi & Faruqi encourages individuals with information regarding Alto's conduct to come forward, including whistleblowers and former employees [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and its effectiveness in treating major depressive disorder [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all persons and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to partake in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will be enrolled in a portfolio monitoring software for updates on the case [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [6].

For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-41944 _________________________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Alto Neuroscience, Inc. (Exact name of registrant a ...

Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO- 207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study e ...

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about a class action lawsuit related to misleading statements made during the company's IPO and subsequent period [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Alto securities during the IPO on February 2, 2024, and up until October 22, 2024 [1]. - A lead plaintiff deadline has been set for September 19, 2025, for those wishing to represent the class [1][3]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Alto Neuroscience - The lawsuit claims that Alto made materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 in treating major depressive disorder [5]. - Specific allegations include that ALTO-100 was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [5]. - The misleading statements resulted in damages to investors when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant a ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) ALTO-100 was less effective in treating MDD than Defendants had led investors ...

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...